logo

Akebia Therapeutics, Inc. (AKBA)



Trade AKBA now with
  Date
  Headline
11/5/2020 8:26:31 AM Akebia Q3 Loss/Shr $0.42 Vs Loss $0.46 Lat Year
10/22/2020 5:08:18 PM Akebia Announces Presentation Of Clinical Data From Its Global INNO2VATE Phase 3 Program
9/3/2020 7:19:52 AM Akebia: PRO2TECT Achieves Primary, Key Secondary Efficacy Endpoints; Does Not Meet Primary Safety MACE Endpoint
8/26/2020 8:05:41 AM Akebia Therapeutics Announces First Commercial Launch Of VAFSEO In Japan
6/29/2020 7:46:11 AM Akebia Announces First Regulatory Approval Of Vadadustat For Treatment Of Anemia Due To Chronic Kidney Disease
6/18/2020 4:02:57 PM Akebia Therapeutics Appoints David Spellman As SVP, CFO And Treasurer
6/10/2020 8:16:44 AM Akebia Therapeutics Announces Data On Different Dosing Regimens Of Ferric Citrate For Iron Deficiency Anemia
6/2/2020 4:34:47 PM Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5/18/2020 8:04:31 AM Akebia Therapeutics Announces Collaboration Partner's Submission Of SNDA For Use Of Riona In Japan
5/11/2020 9:18:54 PM Akebia Prices Underwritten Public Offering Of 11 Mln Shares At $12.00/shr
5/5/2020 7:52:48 AM Akebia Announced Positive Top-Line Results From Global Phase 3 Program Of Vadadustat